Cardiovascular Disease and the

Benefits of Aspirin Therapy
Cardiovascular disease (CVD) is a broad term used to describe a
range of common diseases that affect the heart or blood vessels.
Many common conditions fall under the umbrella of CVD, including
coronary artery disease, heart attack, heart failure, high blood
pressure and stroke. In fact, the term "cardiovascular disease" is
often used interchangeably with heart disease because both terms
refer to diseases of the heart or arteries.
Despite recent
advances in medical research, cardiovascular disease, including
heart attack and stroke, is still the leading killer of men and
women in the United States. It is also the most costly cause of
death in men and women in the U.S., according to the American Heart
Association (AHA).
An estimated 80
million American adults, or 1 in 3, have one or more types of CVD.
It is estimated that cardiovascular disease causes one in every five
deaths in the United States. Nearly every 25 seconds someone in the
U.S. will suffer a coronary event. About every minute someone will
die from one.
Coronary artery
disease is caused by atherosclerosis and often develops into angina
pectoris and myocardial infarction (MI). The condition caused about
445,000 deaths in 2005 and remains the leading single cause of death
in America today. Roughly 16.8 million people have a history of MI
and/or angina.
In 2009, an
estimated 785,000 Americans had a new coronary attack and about
470,000 suffered a recurrent attack. The AHA estimates that an
additional 195,000 silent heart attacks occur each year. Stroke affects 8,500,000 people. Direct and indirect costs
related to the condition are projected to exceed $150 billion
annually.
Aspirin Recommended for Prevention
of Heart Attacks and Strokes
Aspirin has become the
standard treatment for reducing an individual’s risk of a second heart
attack. Studies have found that a daily aspirin regimen for people who have
experienced a previous heart attack reduces the risk of a second heart
attack by about one-third. Aspirin has been incorporated into the American
Heart Association’s clinical guidelines for the secondary prevention of
cardiovascular events. Approximately 50 million Americans now use aspirin
regularly for cardiovascular disease prevention.
Although the CVD benefits of aspirin are well established, the use of
aspirin is associated with the risk of upper gastrointestinal bleeding (UGIB).
The use of aspirin is associated with a 2- to 4-fold increased risk of UGIB.
In addition, aspirin use for CVD is an important cause of gastrointestinal
bleeding-related death.
The use of proton pump
inhibitors (PPIs) such as omeprazole can significantly reduce the risk of
upper gastrointestinal bleeding. The American College of Cardiology with
the AHA issued a Clinical Expert Consensus in 2008 recommending PPIs as the
preferred agents for the therapy and prophylaxis of aspirin-associated
gastrointestinal injury.
|